¹û¶³Ó°Ôº

Intract Pharma, a spin out as part of Professor Abdul Basit’s research throughout the years, focuses on transforming injectable biologic medicines, specifically monoclonal antibodies, into oral medications by enhancing their stability and absorption in the intestinal tract, for chronic inflammatory diseases.

The three-year initiative, named AB-BIOBETTER, is set to revolutionize the treatment of Inflammatory Bowel Diseases (IBD) by developing an oral formulation of adalimumab, aiming to provide patients with a less invasive, more cost-effective, and potentially more potent treatment alternative. Selected during the Eurostars call for projects, AB-BIOBETTER is co-financed by national budgets from Belgium, France, and the UK, with additional support from the European Union.

The AB-BIOBETTER project focuses on creating a daily pill-based version of adalimumab, an anti-TNF-α monoclonal antibody commonly used to treat conditions like Crohn's disease and ulcerative colitis. This innovative approach seeks to replace the current subcutaneous injection method with a more convenient oral pill, promising equal or even improved efficacy. Bio-Sourcing, a Belgian biotech firm known for its sustainable production platform for biotherapeutics, leads the project with significant contributions from its partners.

Vipul Yadav, CEO of Intract Pharma and an alumnus of the School of Pharmacy, said:Ìý"This project aims to achieve the holy grail of biotherapeutics delivery - oral antibody therapeutics. Our combined expertise will transform the treatment paradigm for chronic inflammatory and immune-mediated diseases."

This ambitious project represents a significant leap forward in the oral delivery of monoclonal antibodies, with the potential to greatly enhance treatment options for patients suffering from chronic inflammatory diseases.

Ìý

/pharmacy/people/professor-abdul-basit

Dr Vipul Yadav (vipul.yadav@intractpharma.com)

Professor Abdul Basit (a.basit@ucl.ac.uk)